IGF-1 is regulated via GH binding to a receptor homodimer, located primarily in the liver, which regulates intracellular signaling via a phosphorylation cascade involving the JAK/STAT pathway(1). Cycling (8-12 weeks on, 4 weeks off) mitigates desensitization for all compounds. Hexarelin desensitizes rapidly within 2-4 weeks. GHRP-2 and GHRP-6 show moderate desensitization over 8-12 weeks. It’s a hidden risk factor that nobody’s talking about. I’ve seen guys in the gym who are strong as hell but have the bone density of someone a decade older. You don’t feel your bones getting weaker. For men, bone mineral density peaks in our 20s and slowly declines after that. But the reality is that bone density starts declining for all of us long before we reach old age. When we think about bone problems, we usually think of elderly women with osteoporosis. Following this, GH, IGF-1, skeletal muscle function, body composition, and endocrine-metabolic functions were measured as outcomes. Consistent with this, patients’ waist-hip ratio and GH peak following sermorelin actually showed an age-independent inverse correlation. All 10 elderly men were given 14 days of twice daily injections of either low (0.5 mg) or high dose (1 mg) sermorelin which was then held for 14 days before being restarted for another 14-day period. It was noted that both peptides increased GH by a similar magnitude; however, sermorelin also produced small acute rises in prolactin, FSH, and LH. Sermorelin has been employed in both the diagnosis and treatment of GH deficiency although there is limited research on its use in the setting of hypogonadism (23). GHRH receptor activation leads to cAMP production via the Gs protein/adenylate cyclase and mitogen-activated protein kinase pathways (24). The GHS consist of a variety of synthetic peptide or non-peptide agents that stimulate endogenous GH release. Activation of these two receptors affects several downstream signaling pathways, culminating in a host of antifibrotic, anabolic, vasodilative, cardioprotective, and anti-inflammatory effects (34). The study’s results also emphasize the role of sermorelin as a potent GH and IGF-1 stimulator, which can yield significant increases in lean body mass. Despite these shortcomings, these findings highlight that sermorelin can lead to elevations in IGF-1 when used in conjunction with other GHS, showing the potential role of sermorelin in the treatment of hypogonadism. Additionally, the lack of comparator groups receiving GHS monotherapy and data regarding changes in body composition restrict the ability to fully understand the impact of the individual GHS. More significant increases in IGF-1 levels were observed in the ibutamoren group when compared with placebo (84% vs. 17%, respectively). To date, few long-term, rigorously controlled studies have examined the efficacy and safety of GHSs, although GHSs may improve growth velocity in children, stimulate appetite, improve lean mass in wasting states and in obese individuals, reduce bone turnover, increase fat-free mass, and improve sleep. Growth hormone (GH) increases lean body mass, reduces fat mass, increases exercise tolerance and maximum oxygen uptake, enhances muscle strength, and improves linear growth. IGF-1 testing should occur at least 4–6 weeks into a protocol, as hepatic IGF-1 synthesis lags behind acute GH pulses by 7–14 days. The table below compares the most common ipamorelin stacks across key variables. Choosing the right stack depends on research goals, tolerance for off-target effects, and administration complexity. Dosing typically involves 10–15 mg MK-677 once daily (usually at night) with ipamorelin dosed separately in the morning or pre-workout. Hexarelin produces the strongest GH release of any GHRP but downregulates ghrelin receptors rapidly with repeated use. Stacking ipamorelin with other ghrelin receptor agonists like GHRP-2 or GHRP-6 can achieve this, though with trade-offs. Sermorelin works best when administered 15–20 minutes before ipamorelin to ensure GHRH receptor priming occurs before ghrelin receptor activation. This stack is often dosed once daily before sleep to align with the body's natural nocturnal GH surge, or twice daily (morning and pre-sleep) for researchers focused on maximizing total daily GH exposure. The first category pairs ipamorelin with GHRH analogs to achieve maximum synergistic GH release. For those seeking maximum GH amplitude, monotherapy hits a ceiling because only one receptor pathway is being stimulated. Growth hormone-releasing hormone (GHRH) analogs like CJC-1295 NO DAC act on a completely different receptor class. As ipamorelin-driven fat loss reduces visceral fat, testosterone-to-estrogen ratio can improve passively. At 12 weeks, most users report visible body composition improvement — less fat, more lean tissue, better skin. Most users don't add large amounts of new mass on ipamorelin alone, but they tend to hold and build lean tissue while losing fat — genuine body recomposition. Growth hormone drives a cascade of downstream effects, primarily through IGF-1 (insulin-like growth factor 1) secreted by the liver in response to GH. The GH release ipamorelin triggers stays within physiological range — it amplifies your natural GH pulses rather than flooding your system with supraphysiological levels. Ipamorelin became the benchmark for what a selective growth hormone secretagogue could look like. During the first year, ibutamoren resulted in a significant 1.8-fold increase in 24-h mean GH levels and a 1.5-fold increase in serum IGF-1 levels. Increases in leptin and leptin/body fat ratio may promote earlier satiety and confer further benefit to patients seeking to alter their body composition. This change in weight was attributed to mild fluid retention that was noted with the ibutamoren treatment arm that resolved with treatment cessation.
